Scarica l'app Stockscreener
14.91
0.47%
0.07
Dopo l'orario di chiusura:
14.70
-0.21
-1.41%
Precedente Chiudi:
$14.84
Aprire:
$14.58
Volume 24 ore:
661.44K
Relative Volume:
0.85
Capitalizzazione di mercato:
$1.93B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-5.27%
1M Prestazione:
-21.44%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$14.51
$14.97
Intervallo di 1 settimana:
$14.51
$16.63
Portata 52W:
$14.51
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Nome
Kailera Therapeutics Inc
Settore
Industria
Telefono
508-440-9475
Indirizzo
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
14.91 | 1.92B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-12 | Iniziato | Evercore ISI | Outperform |
| 2026-05-12 | Iniziato | JP Morgan | Overweight |
| 2026-05-12 | Iniziato | Jefferies | Buy |
| 2026-05-12 | Iniziato | Leerink Partners | Outperform |
| 2026-05-12 | Iniziato | TD Cowen | Buy |
| 2026-05-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Kailera Therapeutics Inc Borsa (KLRA) Ultime notizie
Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week LowWhat's Next? - marketbeat.com
Kailera Therapeutics (KLRA) grants CTO 220,000 stock options - Stock Titan
Kailera Therapeutics (KLRA) CTO reports no shares in first ownership filing - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7%Should You Sell? - marketbeat.com
symbol__ Stock Quote Price and Forecast - CNN
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - marketbeat.com
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - marketbeat.com
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - marketbeat.com
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Stock Falls 12.5%, Leaving Market Value Just $930 Million Above Cash - ts2.tech
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - marketbeat.com
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - marketbeat.com
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - marketbeat.com
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics shares dip amid Phase 3 ob... - Pluang
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Q2 loss widens 285% to $111.3M on R&D surge; cash runway extends to mid-2028 - scanx.trade
Kailera Therapeutics Submits Q2 2026 10-Q Highlighting Financial Status and Operational Risks - Kalkine Media
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Australia
Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary - TradingView
KLRA: Q2 net loss rose to $111.3M on higher R&D; $1.17B cash post-IPO funds operations into mid-2028 - tradingview.com
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings | KLRA Stock News - Quiver Quantitative
Kailera Therapeutics, Inc. Announces Appointment of Nur Nicholson as Chief Technology Officer, Effective August 31, 2026 - marketscreener.com
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - The Manila Times
Obesity focused Kailera appoints Nur Nicholson as CTO - The Pharma Letter
Kailera Therapeutics Inc expected to post a loss of 75 cents a shareEarnings Preview - TradingView
Jiangsu Hengrui discloses 8.9% Kailera Therapeutics (KLRA) stake in ownership filing - Stock Titan
Bain Capital Xiv General Partner, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. Revenue Breakdown – NASDAQ:KLRA - TradingView
Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat
Patent fight erupts around next generation of multibillion-dollar GLP-1 weight-loss drugs - The Business Journals
Yuting Liu Net Worth (2026) - GuruFocus
Kailera Therapeutics Inc Azioni (KLRA) Dati Finanziari
Non sono disponibili dati finanziari per Kailera Therapeutics Inc (KLRA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):